{"schema_version":"1.0","type":"article","title":"瘦瘦針全加失明警語，猛健樂台灣仿單是下一個","url":"https://drugnews.com.tw/articles/2026-11-14-glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-14-glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan.md","lang":"zh-Hant","date":"2026-11-14","publish_at":"2026-11-14T08:00:00+08:00","updated_at":"2026-11-14","category":"商業分析系列","topic":"商業分析系列","tags":["瘦瘦針","GLP-1","藥物安全","猛健樂","食藥署"],"summary":"FDA 11 月 9 日要求所有 GLP-1 仿單加註罕見視神經病變 NAION，連猛健樂與口服 Foundayo 都在內；台灣只先處理 semaglutide，食藥署 11 月 10 日啟動再評估。我們拆解 1.7 倍風險的分母、官司與台灣仿單的下一步。","key_points":["FDA 於 2026 年 11 月 9 日要求所有 GLP-1 藥物在仿單警語段加註 NAION，涵蓋 semaglutide、tirzepatide 與口服 orforglipron。","FDA 統合 126 個試驗只找到 15 個很可能病例，發生率每 10 萬人年 6.4 對 3.8；真實世界與 SGLT-2 相比風險比 1.19，未達統計顯著。","台灣食藥署 2026 年 6 月只要求 semaglutide 藥品加註，11 月 10 日宣布對整類 GLP-1 啟動安全性再評估。"],"facts":[{"claim":"FDA required class-wide NAION labeling for GLP-1 RAs","value":"2026-11-09","unit":"date","as_of":"2026-11-09","source":"FDA DSC"},{"claim":"GLP-1 RA NAION incidence in RCT meta-analysis","value":6.4,"unit":"per 100,000 PY","as_of":"2026-11-09","source":"FDA DSC"},{"claim":"Comparator NAION incidence in RCT meta-analysis","value":3.8,"unit":"per 100,000 PY","as_of":"2026-11-09","source":"FDA DSC"},{"claim":"RCTs in FDA meta-analysis","value":126,"unit":"trials","as_of":"2026-11-09","source":"FDA DSC"},{"claim":"Participants in FDA meta-analysis","value":134253,"unit":"patients","as_of":"2026-11-09","source":"Pharmacy Times"},{"claim":"Probable NAION events in meta-analysis (10 GLP-1, 5 placebo)","value":15,"unit":"events","as_of":"2026-11-09","source":"Pharmacy Times"},{"claim":"Sentinel HR GLP-1 vs SGLT-2 (95% CI 0.91-1.54)","value":1.19,"unit":"HR","as_of":"2026-11-09","source":"FDA DSC"},{"claim":"Sentinel HR GLP-1 vs DPP-4 (95% CI 1.02-2.01)","value":1.43,"unit":"HR","as_of":"2026-11-09","source":"FDA DSC"},{"claim":"Sentinel incidence GLP-1 / SGLT-2 / DPP-4","value":"30-32 / 31 / 26","unit":"per 100,000 PY","as_of":"2026-11-09","source":"Pharmacy Times"},{"claim":"Background NAION incidence adults >50","value":"2.3-10.2","unit":"per 100,000 per year","as_of":"2026-11-09","source":"Pharmacy Times"},{"claim":"EMA: NAION very rare with semaglutide","value":"up to 1 in 10,000","unit":"frequency","as_of":"2025-06-06","source":"EMA"},{"claim":"MHRA Yellow Card suspected NAION reports with semaglutide to 2025-08-01","value":3,"unit":"reports","as_of":"2026-02-05","source":"MHRA"},{"claim":"Semaglutide packs dispensed in UK over 5 years","value":10.2,"unit":"million","as_of":"2026-02-05","source":"MHRA"},{"claim":"FDA removed suicidal ideation warning (91 trials, 107,910 patients)","value":"2026-01-13","unit":"date","as_of":"2026-01-13","source":"FDA"},{"claim":"TFDA required NAION labeling for semaglutide products","value":"2026-06","unit":"date","as_of":"2026-11-10","source":"自由時報"},{"claim":"TFDA GLP-1 suspected ADR reports this year (39 for weight loss)","value":63,"unit":"reports","as_of":"2026-11-10","source":"自由時報"},{"claim":"Ozempic (胰妥讚) Taiwan sales rank 2025","value":10,"unit":"rank","as_of":"2026-04-07","source":"世界新聞網"},{"claim":"Mounjaro Q3 2026 revenue","value":10.723,"unit":"USD billion","as_of":"2026-10-29","source":"藥時事 2026-11-02 (Lilly Q3)"},{"claim":"Wegovy pill US prescriptions Q3 2026","value":3.6,"unit":"million","as_of":"2026-11-04","source":"TimesLIVE/Reuters"},{"claim":"Foundayo ATTAIN-OSA AHI reduction (no PAP) vs placebo -6.3%","value":-43.8,"unit":"%","as_of":"2026-11-09","source":"Eli Lilly"},{"claim":"SUSTAIN-6 retinopathy complications semaglutide vs placebo","value":"3.0% vs 1.8%","unit":"%","as_of":"2016-11-10","source":"NEJM"},{"claim":"GLP-1 NAION MDL","value":"3163","unit":"MDL No.","as_of":"2025-12-17","source":"Levin Papantonio"}],"sections":["01｜「風險 1.7 倍」是 15 個病例算出來的","02｜FDA 最晚出手，卻管得最寬","03｜黑框警語都沒擋住處方，這張也擋不住","04｜生意怎麼變：官司、眼科門診與藥丸的賣點","05｜台灣：週纖達已改仿單，猛健樂還在排隊","06｜我們可能錯在哪裡","參考資料"],"references":[{"title":"FDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare But Serious Eye Condition","source":"U.S. FDA","date":"2026-11-09","url":"https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential"},{"title":"FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk","source":"Pharmacy Times","date":"2026-11-10","url":"https://www.pharmacytimes.com/view/fda-requires-class-wide-glp-1-ra-labeling-changes-for-potential-naion-risk"},{"title":"FDA示警！「瘦瘦針」恐增視神經病變風險 食藥署將啟動安全性再評估","source":"自由時報","date":"2026-11-10","url":"https://news.ltn.com.tw/news/life/breakingnews/5636292"},{"title":"瘦瘦針恐釀失明！美FDA發警訊 食藥署啟動安全性再評估","source":"中時新聞網","date":"2026-11-10","url":"https://www.chinatimes.com/realtimenews/20261110003523-260405"},{"title":"瘦瘦針藏風險 FDA令加警語","source":"工商時報","date":"2026-11-11","url":"https://www.ctee.com.tw/news/20261111700138-439901"},{"title":"October - December 2024","source":"Potential Signals of Serious Risks Identified by FDA","date":"2025-03-31","url":"https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2024-new-safety-information-or-potential-signals-serious-risks-identified-fda"},{"title":"PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines","source":"European Medicines Agency","date":"2025-06-06","url":"https://www.ema.europa.eu/pt/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy"},{"title":"The use of semaglutide medicines and risk of NAION","source":"World Health Organization","date":"2025-06-27","url":"https://www.who.int/news/item/27-06-2025-27-06-2025-semaglutide-medicines-naion"},{"title":"Semaglutide: risk of NAION","source":"MHRA Drug Safety Update","date":"2026-02-05","url":"https://www.gov.uk/drug-safety-update/semaglutide-wegovy-ozempic-and-rybelsus-risk-of-non-arteritic-anterior-ischemic-optic-neuropathy-naion"},{"title":"FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RA Medications","source":"U.S. FDA","date":"2026-01-13","url":"https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp"},{"title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6","source":"New England Journal of Medicine","date":"2016-11-10","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1607141"},{"title":"Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity","source":"Eli Lilly","date":"2026-11-09","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-foundayo-orforglipron-significantly-reduced-obstructive"},{"title":"Novo Nordisk lifts 2026 outlook as Wegovy pill surges","source":"TimesLIVE／Reuters","date":"2026-11-04","url":"https://www.timeslive.co.za/news/world/2026-11-04-novo-nordisk-lifts-2026-outlook-as-wegovy-pill-surges/"},{"title":"減重針降價，禮來營收增39%甩開諾和","source":"藥時事","date":"2026-11-02","url":"https://drugnews.com.tw/articles/2026-11-02-lilly-q3-2026-glp1-price-cut-volume-novo.html"},{"title":"Federal court creates new MDL for Ozempic and other GLP-1 drugs linked to vision loss","source":"Levin Papantonio（新聞稿","date":"2025-12-17","url":"https://business.mammothtimes.com/mammothtimes/article/gnwcq-2025-12-17-levin-papantonio-federal-court-creates-new-mdl-for-ozempic-and-other-glp-1-drugs-linked-to-vision-loss-naion"},{"title":"Hundreds of lawsuits allege GLP-1s caused permanent vision loss","source":"WCAX／Gray News","date":"2026-09-22","url":"https://www.wcax.com/2026/09/22/hundreds-lawsuits-allege-glp-1s-like-ozempic-wegovy-mounjaro-caused-permanent-vision-loss/"},{"title":"GLP-1 Drugs Under Scrutiny as Lawsuits Allege NAION Risk","source":"Review of Optometry","date":"2026-09-22","url":"https://www.reviewofoptometry.com/article/glp1-drugs-under-scrutiny-as-lawsuits-allege-naion-risk"},{"title":"台灣10大暢銷藥物 癌藥占6項 瘦瘦針首進榜","source":"世界新聞網","date":"2026-04-07","url":"https://www.worldjournal.com/wj/story/121221/9425242"},{"title":"減重藥丸諾和贏4倍，禮來新病人拿下三到四成","source":"藥時事","date":"2026-11-10","url":"https://drugnews.com.tw/articles/2026-11-10-novo-wegovy-pill-lilly-foundayo-oral-obesity-race.html"}],"images":[{"alt":"圖1｜倍數背後的絕對數字","url":"https://drugnews.com.tw/assets/articles/glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan/figure-01.png"},{"alt":"圖2｜各國監管時間線：先 semaglutide，FDA 一次全類別","url":"https://drugnews.com.tw/assets/articles/glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan/figure-02.png"},{"alt":"圖3｜NAION：視神經前端的一次缺血","url":"https://drugnews.com.tw/assets/articles/glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan/figure-03.png"},{"alt":"圖4｜誰的仿單已經寫了、誰還沒寫","url":"https://drugnews.com.tw/assets/articles/glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-14）。瘦瘦針全加失明警語，猛健樂台灣仿單是下一個。https://drugnews.com.tw/articles/2026-11-14-glp1-naion-vision-warning-fda-classwide-mounjaro-taiwan.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"「FDA 於 2026 年 11 月 9 日要求所有 GLP-1 藥物在仿單警語段加註 NAION，涵蓋 semaglutide、tirzepatide 與口服 orforglipron」有哪些關鍵變化？","a":"FDA 於 2026 年 11 月 9 日要求所有 GLP-1 藥物在仿單警語段加註 NAION，涵蓋 semaglutide、tirzepatide 與口服 orforglipron。"},{"q":"「FDA 統合 126 個試驗只找到 15 個很可能病例，發生率每 10 萬人年 6.4 對 3.8」有哪些關鍵變化？","a":"FDA 統合 126 個試驗只找到 15 個很可能病例，發生率每 10 萬人年 6.4 對 3.8；真實世界與 SGLT-2 相比風險比 1.19，未達統計顯著。"},{"q":"「台灣食藥署 2026 年 6 月只要求 semaglutide 藥品加註，11 月 10 日宣布對整類 GLP-1 啟動安全性再評估」有哪些關鍵變化？","a":"台灣食藥署 2026 年 6 月只要求 semaglutide 藥品加註，11 月 10 日宣布對整類 GLP-1 啟動安全性再評估。"}]}